SCI Pharmtech Inc
TWSE:4119
Gross Margin
SCI Pharmtech Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
TW |
S
|
SCI Pharmtech Inc
TWSE:4119
|
9.9B TWD |
27%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
793.6B USD |
81%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
69%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
85%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
246.5B CHF |
73%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
235.8B USD |
81%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
180B GBP |
82%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
200.9B CHF |
75%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
166.1B USD |
68%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
148.9B USD |
74%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on SCI Pharmtech Inc's most recent financial statements, the company has Gross Margin of 27.1%.